Whitepaper: Virus vaccine research – accelerated workflows

Posted: 7 January 2021 | | No comments yet

Discover how workflows are being accelerated to speed up the vaccine research and development process while maintaining safety and immunogenicity.

Successfully developing a vaccine typically takes years and requires millions of research dollars to reach commercialisation. It is a complex process with a high failure rate.

With millions of people worldwide contracting coronavirus disease 2019 (COVID-19), vaccine developers face the enormous challenge of producing a safe, effective vaccine in months to stop the spread of the deadly disease.  

The pandemic is changing vaccine development – stakeholders collaborating to reach the common goal.